22nd Century Group, Inc. (XXII) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on June 24, 2024, by 22nd Century Group, Inc., a Nevada corporation trading on the NASDAQ Capital Market under the symbol "XXII". The report discloses a specific financial event regarding the company's indebtedness involving its former subsidiary, GVB Biopharma ("GVB").
Key Financial Metrics
The filing details a reduction in outstanding principal indebtedness with JGB Partners, LP and related affiliates ("JGB").
- Principal Reduction: $1.5 million paid on June 24, 2024.
- Remaining Principal: Approximately $8.3 million outstanding after the payment.
- Extended Obligation: $0.5 million payable by GVB has been extended to December 31, 2024.
The filing does not provide data on revenue, profit, cash flow, margins, or overall liquidity beyond the specific debt transaction described.
Material Changes
The primary material change is the scheduled principal and interest payment made by GVB, which reduced the total outstanding principal owed to JGB by $1.5 million. Additionally, the repayment schedule for the remaining $0.5 million balance was modified, extending the due date to December 31, 2024.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of general risks. The disclosure is limited to the execution of the debt payment and the extension of the remaining note balance. A press release dated June 25, 2024, regarding this transaction is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the total outstanding debt balance of approximately $8.3 million with JGB Partners.
- Confirm the terms of the extended $0.5 million payment due December 31, 2024.
- Review the attached press release (Exhibit 99.1) for additional context on the debt restructuring.
- Check subsequent filings for updates on the company's liquidity position given the remaining debt obligations.